Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 26.4% in Q3 FY26, against a low of 26.3% in Q2 FY26. ROE, at 86.0%, is far above it because equity is small against the capital the business uses.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 101.2% | 107.5% | 102.3% | 86.0% |
| ROIC | 26.6% | 30.2% | 26.3% | 26.4% |
Debt
Net debt is 4.45× a year’s EBITDA. Debt is 1.17× equity, against 1.62× in Q2 FY26.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 1.6× | 1.3× | 1.6× | 1.2× |
| Net debt / EBITDA | 4.1× | 3.6× | 4.8× | 4.5× |
Cash cycle, in days
Customers pay in 107 days, inventory is held 469 days and suppliers are paid in 149. Cash is tied up for 426 days between paying for goods and being paid.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Cash cycle | 389 | 387 | 402 | 426 |
| Days to pay suppliers | 178 | 148 | 169 | 149 |
| Days to be paid | 113 | 107 | 108 | 107 |
Per share, from Q4 FY25
Since Q4 FY25, per share: free cash flow has grown 120.5%; revenue has grown 33.5%; book value has grown 52.7%.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Free cash flow | 1.0× | 1.3× | 2.0× | 2.2× |
| Revenue | 1.0× | 1.1× | 1.2× | 1.3× |
| Book value | 1.0× | 1.2× | 1.3× | 1.5× |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 86.02% | 102.29% | 107.46% | 101.16% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
8 | 9 | 8 | 7 | |
| 20.97% | 21.97% | 24.54% | 21.59% | ||
ROIC |
26.42% | 26.33% | 30.18% | 26.61% | |
Return on Tangible Assets |
54.66% | 57.79% | 56.50% | 45.79% | |
Average Days of Receivables |
106.51 | 107.56 | 106.99 | 112.87 | |
Free Cash Flow per Share |
22.04 | 20.38 | 13.22 | 10.00 | |
Free Cash Flow |
19,661.00 | 18,190.00 | 11,823.00 | 8,972.00 | |
Capital Expenditures |
(10,984.00) | (9,893.00) | (8,657.00) | (7,841.00) | |
| Other line items | |||||
Cash ROIC |
21.34% | 18.61% | 15.59% | 11.76% | |
Accounts Receivable Turnover |
3.87 | 3.92 | 4.11 | 3.90 | |
Accounts Payable Turnover |
2.81 | 2.60 | 2.93 | 2.57 | |
Inventory Turnover |
0.93 | 0.95 | 1.04 | 1.04 | |
Average Days of Payables |
149.44 | 168.70 | 147.98 | 177.65 | |
Days of Inventory on Hand |
469.35 | 463.51 | 427.53 | 453.91 | |
Tax Rate |
(0.21) | (0.20) | (0.19) | (0.20) | |
Research and Development Expense of Revenue |
17.78% | 18.32% | 19.53% | 20.46% | |
Selling, General and Administrative Expense of Revenue |
14.60% | 15.36% | 16.00% | 17.02% | |
Share Based Compensation of Revenue |
0.81% | 0.81% | 0.88% | 0.96% | |
Interest Coverage |
— | 83.46 | — | — | |
Operating CF/Net income |
1.11 | 1.05 | 0.81 | 0.81 | |
Depreciation/Fixed assets |
0.07 | 0.07 | 0.08 | 0.08 | |
Capex/Depreciation |
(5.05) | (4.71) | (4.24) | (3.93) | |
Revenue per Share |
96.94 | 89.27 | 80.77 | 72.64 | |
Operating CF per Share |
34.36 | 31.47 | 22.90 | 18.74 | |
Capex per Share |
(12.32) | (11.09) | (9.68) | (8.74) | |
Capex to Sales |
0.13 | 0.12 | 0.12 | 0.12 |